Metastatic squamous-cell NSCLC is an incurable disease associated with a dismal 5 year OS of <5%; treatments delivering improvements to survival are therefore a key treatment goal in this disease. Despite recent approvals of Portrazza, Opdivo and Keytruda for metastatic squamous-cell NSCLC, surveyed oncologists highlight that novel therapies with improved clinical efficacy are still an area of high unmet need.  This report investigates key drivers of prescribing in squamous-cell NSCLC, and identifies key areas of unmet need in the indication. 

 

 

 

 

Table of contents

  • Detailed, Expanded Analysis: Metastatic Squamous Cell Non-Small Cell Lung Cancer
    • Treatment Drivers and Goals
      • Overview
      • Stated Versus Derived Importance of Treatment Drivers and Goals
        • Stated Versus Derived Importance of Key Treatment Drivers and Goals
      • Physician Rating of Treatment Drivers and Goals in Metastatic Squamous-Cell Non-Small-Cell Lung Cancer
        • Efficacy
        • Safety and Tolerability
        • Non-Clinical Factors
    • Product Performance Against Treatment Drivers and Goals
      • Overview
      • Rationale for Drug Selection
      • Current Brand Performance on Key Treatment Drivers and Goals
        • Efficacy
        • Safety and Tolerability
        • Non-Clinical Factors
    • Assessment of Unmet Need
      • Overview
      • Overall Satisfaction with Current Treatment
      • Physician Rating of Unmet Need in Metastatic Squamous-Cell Non-Small-Cell Lung Cancer
        • Efficacy
        • Safety and Tolerability
        • Non-Clinical Factors
      • Unmet Need in Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in Metastatic Squamous-Cell Non-Small-Cell Market and Emerging Therapy Insights
        • Opportunity: A New Agent That Improves OS in Metastatic Squamous-Cell Non-Small-Cell Lung Cancer
        • Opportunity: A Novel Agent That Improves PFS in Metastatic Squamous-Cell Non-Small-Cell Lung Cancer
        • Opportunity: A New Biomarker-Driven Therapy Predictive of Response
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Scenario 1
        • Scenario 2
    • Appendix A: Bibliography
      • Bibliography

Author(s): Khurram Nawaz, MSc

Khurram Nawaz is a director in the oncology team at Decision Resources Group. Mr. Nawaz manages a team of analysts who conduct extensive primary and secondary market research on several oncology indications across the major pharmaceutical markets. He also provides sales and client support on syndicated and custom oncology products, translating domain knowledge into actionable insights. Previously, Mr. Nawaz was a principal analyst in the oncology team at Decision Resources Group, where he developed considerable expertise in forecasting complex oncology and hemato-oncology drug markets, and conducted detailed primary research with physicians and payers across multiple geographies. He has in-depth expertise in immuno-oncology, non-small-cell lung cancer, prostate cancer, multiple myeloma, and other solid and hematological malignancies. Prior to joining Decision Resources Group, Mr. Nawaz was a scientist at GlaxoSmithKline, where he contributed to the development of candidate drugs for schizophrenia and cognitive disorders. He holds a in biotechnology from the École Supérieure d'Ingénieurs de Luminy (now Polytech Marseille), University of Aix-Marseille, and a in life sciences from the Pierre and Marie Curie–Paris VI University.


Related Reports

Non-Small-Cell Lung Cancer - Landscape & Forecast - Disease Landscape & Forecast

Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need, remains a key area of focus for drug developers.

View Details

Non-Small-Cell Lung Cancer | Disease Landscape and Forecast | G7 | 2020

Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need, remains a key area of focus for drug developers. NSCLC is defined by driver mutations, and treatment is becom...

View Details

Small Cell Lung Cancer - Landscape & Forecast - Disease Landscape & Forecast

For decades, the treatment landscape of small-cell lung cancer (SCLC) has been dominated by chemotherapy or chemoradiotherapy. In 2018, BristolMyers Squi...

View Details

Non-Small-Cell Lung Cancer - Geographic Focus: China - Non-Small-Cell Lung Cancer - China In-Depth (China)

Non-small-cell lung cancer (NSCLC)—the leading cause of cancer-related deaths in China—has a highly dynamic drug development pipeline, with multiple targeted and biomarker-driven therap...

View Details